Guardant Health rises
Guardant Health Shares Rise After ADLT Status for Shield Blood Test
Guardant Health said the CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that can't be obtained by any other method, and for FDA-approved tests.
CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...
Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...
(RTTNews) - Guardant Health, Inc. (GH) Tuesday announced that the Centers for Medicare & Medicaid Services or CMS has granted Advanced Diagnostic Laboratory Test or ADLT status to its Shield ...
The company discussed its recent ADLT pricing update for Shield, its implications for commercial strategy, and plans for expanding its product offerings and market reach. Guardant Health is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback